Relation of Risk of Stroke in Patients With Atrial Fibrilla Patients Treated With Rivaroxaban and Warfarin in the Direct Factor Xa Inhibition Compared With Vitamin K A Stroke and Embolism Trial in Atrial Fibrillation Trial)

American Journal of Cardiology

119, 1989-1996

DOI: 10.1016/j.amjcard.2017.03.028

Citation Report

#	Article	IF	Citations
1	Impact of BMI on Clinical Outcomes of NOAC Therapy in Daily Care - Results of the Prospective Dresden NOAC Registry (NCT01588119). International Journal of Cardiology, 2018, 262, 85-91.	3.2	78
2	Pharmacy Student Monitoring of Direct Oral Anticoagulants. Journal of Pharmacy Practice, 2018, 31, 462-468.	1.3	9
3	The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: Executive Summary. Europace, 2018, 20, 1231-1242.	8.4	226
4	The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation. European Heart Journal, 2018, 39, 1330-1393.	14.7	1,815
5	Anticoagulation at the Extremes of Body Weight: Choices and Dosing. Expert Review of Hematology, 2018, 11, 817-828.	2.7	28
6	Short-Term Outcomes of Apixaban Versus Warfarin in Patients With Atrial Fibrillation. Circulation, 2019, 139, 2301-2303.	24.6	4
7	Effects of Body Mass Index on the Safety and Effectiveness of Direct Oral Anticoagulants: A Retrospective Review. Journal of Thrombosis and Thrombolysis, 2019, 48, 359-365.	2.2	34
8	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Circulation, 2019, 139, 2292-2300.	24.6	103
9	Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Among Morbidly Obese Patients With Atrial Fibrillation. American Heart Journal, 2019, 212, 113-119.	3.3	79
10	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. American Journal of Therapeutics, 2019, 26, e679.	1.1	4
11	Relationship Between Body Mass Index and Outcomes in Patients With Atrial Fibrillation Treated With Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. European Heart Journal, 2019, 40, 1541-1550.	14.7	115
12	Obesity Paradox in Atrial Fibrillation: Implications for Outcomes and Relationship With Oral Anticoagulant Drugs. American Journal of Cardiovascular Drugs, 2020, 20, 125-137.	3.7	16
13	Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis. American Journal of Cardiovascular Drugs, 2020, 20, 51-60.	3.7	71
14	The Obesity Paradox for Outcomes in Atrial Fibrillation: Evidence From an Exposure-Effect Analysis of Prospective Studies. Obesity Reviews, 2020, 21, e12970.	9.2	44
15	Use of Direct Oral Anticoagulants in Morbidly Obese Patients. Pharmacotherapy, 2020, 40, 72-83.	4.3	37
16	Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 1076029620954910.	2.2	5
17	Non-Vitamin K vs Vitamin K Oral Anticoagulants in Patients Aged > 80 Year With Atrial Fibrillation and Low Body Weight. European Journal of Clinical Investigation, 2020, 50, e13335.	4.4	22
18	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2020, 36, 1847-1948.	3.8	582

#	Article	IF	Citations
19	Efficacy and Safety of Direct Oral Anticoagulants for Atrial Fibrillation Across Body Mass Index Categories. Journal of the American Heart Association, 2020, 9, e017383.	5.8	14
20	Influence of BMI and Geographical Region on Prescription of Oral Anticoagulants in Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. European Journal of Internal Medicine, 2020, 80, 35-44.	4.2	13
21	A Single Center Retrospective Cohort Study Evaluating Use of Direct Oral Anticoagulants (DOACs) in Morbidly Obese Veteran Population. Thrombosis Research, 2020, 192, 124-130.	2.9	25
22	Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients. American Journal of Cardiology, 2020, 127, 176-183.	2.4	19
23	Thromboembolic and Bleeding Risk in Obese Patients With Atrial Fibrillation According to Different Anticoagulation Strategies. International Journal of Cardiology, 2020, 318, 67-73.	3.2	15
24	Challenging Management of a Patient With Severe Bilateral Deep Vein Thrombosis. Journal of Investigative Medicine High Impact Case Reports, 2020, 8, 2324709620910288.	0.8	3
25	Effectiveness and Safety of Rivaroxaban Versus Warfarin in Obese Nonvalvular Atrial Fibrillation Patients: Analysis of Electronic Health Record Data. Current Medical Research and Opinion, 2020, 36, 1081-1088.	2.9	33
26	Impact of Body Mass Index on Real-World Outcomes of Rivaroxaban Treatment in Japanese Patients With Non-Valvular Atrial Fibrillation. Heart and Vessels, 2020, 35, 1125-1134.	1.8	12
27	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Journal of the American College of Cardiology, 2021, 77, 511-525.	12.0	17
28	The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations. American Journal of Cardiovascular Drugs, 2021, 21, 283-297.	3.7	14
29	Edoxaban Versus Warfarin in Patients With Atrial Fibrillation at the Extremes of Body Weight: An Analysis From the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2021, 121, 140-149.	4.6	40
30	Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-Valvular Atrial Fibrillation (NVAF) Patients With Obesity in a US Population. Journal of Medical Economics, 2021, 24, 550-562.	3.0	5
31	Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients With Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: A Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2022, 36, 749-761.	4.1	20
32	The “Obesity Paradox” and the Use of NOAC. , 2021, .		1
33	Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation. Stroke, 2021, 52, 521-530.	9.1	27
34	Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues. Hamostaseologie, 2021, 41, 035-041.	1.5	1
35	Efficacy and Safety of Direct Oral Anticoagulant in Morbidly Obese Patients With Atrial Fibrillation: Systematic Review and Meta-Analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 325-335.	5.0	19
36	Safety and Efficacy of Rivaroxaban and Apixaban in Patients With Increased Body Mass: A Systematic Review. Clinical Drug Investigation, 2021, 41, 353-369.	3.1	11

#	Article	IF	Citations
37	Clinical Uncertainty for the Use of Rivaroxaban in Obesity. Journal of Thrombosis and Haemostasis, 2021, 19, 870-871.	5.0	0
38	The Impact of Underweight and Obesity on Outcomes in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis on the Obesity Paradox. Clinical Cardiology, 2021, 44, 599-608.	3.1	27
39	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	8.4	1,074
40	Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients With Obesity and Polypharmacy in the United States (US). Advances in Therapy, 2021, 38, 3771-3788.	5.0	7
41	Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Extreme Body Weight. European Journal of Clinical Investigation, 2022, 52, e13658.	4.4	7
42	Economic Burden of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation Patients With Obesity and Polypharmacy. Journal of Comparative Effectiveness Research, 2021, 10, 1235-1250.	2.7	5
43	Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients With Obesity and Diabetes. Journal of Diabetes and Its Complications, 2021, 35, 108029.	3.4	9
44	Direct-Acting Oral Anticoagulant Choice for Stroke Prevention in Obese Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2021, 37, 1489-1492.	3.8	15
45	Direct Oral Anticoagulants in Patients With Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO). Journal of Clinical Medicine, 2021, 10, 4185.	3.8	13
46	Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients With Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2020, 46, 970-976.	4.1	13
47	Impact of Weight on the Efficacy and Safety of Direct-Acting Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Meta-Analysis. Europace, 2020, 22, 361-367.	8.4	28
48	Direct Oral Anticoagulants in Obesity: An Updated Literature Review. Annals of Pharmacotherapy, 2020, 54, 1144-1158.	2.9	37
49	Atrial Fibrillation in the Cardiometabolic Patient. Minerva Medica, 2019, 110, 157-167.	0.8	18
50	Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients With Obesity and Diabetes. Diabetes Therapy, 2021, 12, 3167-3186.	4.4	7
51	Effectiveness of Direct Oral Anticoagulants in Obese Adults With Atrial Fibrillation: A Systematic Review of Systematic Reviews and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 732828.	3.2	15
52	Review on Atrial Fibrillation. Journal of Innovations in Cardiac Rhythm Management, 2017, 8, 2958-2962.	1.0	0
53	Updates on Direct Oral Anticoagulants in the Management of Atrial Fibrillation. European Journal of Arrhythmia & Electrophysiology, 2019, 5, 24.	0.0	0
54	2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants. Korean Journal of Medicine, 2019, 94, 57-82.	0.3	1

#	Article	IF	Citations
55	Efficacy and Safety of Direct Factor Xa Inhibitors Versus Warfarin in Prevention of Primary and Secondary Ischemic Strokes in Non-Valvular Atrial Fibrillation: A Literature Review. Cureus, 2020, 12, e9400.	1.3	4
56	Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review. Seminars in Thrombosis and Hemostasis, 2020, 46, 932-969.	4.1	46
57	The 2020 CCS Atrial Fibrillation Guidelines for Pharmacists: Top 10 Takeaways. Canadian Pharmacists Journal, 2022, 155, 107-118.	1.8	5
58	Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients With Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs. American Journal of Cardiology, 2022, 163, 43-49.	2.4	7
59	Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin Among Obese Patients With Atrial Fibrillation. CJC Open, 2022, 4, 395-405.	1.8	7
60	Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients With Obesity and Polypharmacy. American Journal of Cardiovascular Drugs, 2022, 22, 425-436.	3.7	14
61	Association Between Body Mass Index and Clinical Outcomes in Patients With Non-Valvular Atrial Fibrillation Receiving Direct Oral Anticoagulants: A New Piece of Evidence on the Obesity Paradox From China. Cardiovascular Drugs and Therapy, 2023, 37, 715-727.	4.1	11
62	Safety and Efficacy of Direct Oral Anticoagulants in Comparison With Warfarin Across Different BMI Ranges: A Systematic Review and Meta-Analysis. Annals of Medicine and Surgery, 2022, 77, 103610.	1.7	11
63	Comparing Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Extreme Obesity. Journal of Pharmacy Practice, 2023, 36, 1375-1382.	1.3	6
64	Metabolisches Syndrom und Vorhofflimmern. Herzschrittmachertherapie Und Elektrophysiologie, 2022, 33, 367-372.	1.1	5
65	Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review. Clinical Pharmacokinetics, 2022, 61, 1677-1695.	4.0	8
66	Predicting Thromboembolism in Hospitalized Patients With Ventricular Thrombus. Reviews in Cardiovascular Medicine, 2022, 23, 390.	2.5	0
67	Safety and Efficacy of Apixaban, Dabigatran and Rivaroxaban in Obese and Morbidly Obese Patients With Heart Failure and Atrial Fibrillation: A Real-World Analysis. PACE - Pacing and Clinical Electrophysiology, 2023, 46, 50-58.	1.3	6
68	Direct Oral Anticoagulants for Stroke Prevention in Special Populations: Beyond the Clinical Trials. Biomedicines, 2023, 11, 131.	4.9	12
69	Lifestyle Changes in Atrial Fibrillation Management and Intervention. Journal of Cardiovascular Electrophysiology, 2023, 34, 2163-2178.	2.8	21
70	Better Survival in Morbidly Obese Patients With Atrial Fibrillation Treated With Non-Vitamin K-Dependent Oral Anticoagulants. Journal of the Saudi Heart Association, 2023, 35, 7-15.	1.5	1
71	Prevention of Thromboembolic Complications in Patients With Atrial Fibrillation and Obesity. Annales Academiae Medicae Silesiensis, 2023, 77, 60-66.	0.4	0
72	Obesity and Atrial Fibrillation: Prevalence, Pathogenesis, and Prognosis. Progress in Cardiovascular Diseases, 2023, 78, 34-42.	9.7	36

#	Article	IF	Citations
73	2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 2024, 83, 109-279.	12.0	942
74	Direct-Acting Oral Anticoagulants in Patients at Extremes of Body Weight: A Review of Pharmacological Considerations and Clinical Implications. TH Open, 2024, 08, e31-e41.	1.8	16
75	Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation. Circulation, 2024, 149, 932-943.	24.6	31
76	2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2024, 149, e1-e156.	24.6	2,614
77	Characterization of Antithrombotic Regimens for Patients With Nonvalvular Atrial Fibrillation and Obesity Discharged From Cardiology Wards. Canadian Journal of Hospital Pharmacy, 2024, 77, e3425.	0.6	0
78	Obese Patients With Atrial Fibrillation Are More Efficiently Protected From Thrombosis Under Warfarin or Xabans Compared to Non-Obese Patients; A Systematic Review and Meta-Analysis of Six Randomized Controlled Trials. Thrombosis Research, 2024, 238, 88-96.	2.9	1
79	Pharmacokinetics of Single-Dose Rivaroxaban Under Fed State in Obese vs. Non-Obese Subjects: An Open-Label Controlled Clinical Trial (RIVOBESE-PK). Clinical and Translational Science, 2024, 17, e13853.	4.1	2
80	Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) With Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2024, 13, 3784.	3.8	23
81	Treatment of Atrial Fibrillation and Venous Thromboembolism With Factor Xa Inhibitors in Severely Obese Patients. Journal of Thrombosis and Haemostasis, 2024, 22, 3500-3509.	5.0	11
82	Controversies and Challenges of Anticoagulation Therapy in Obesity. Expert Opinion on Pharmacotherapy, 2025, 26, 381-431.	3.5	2
83	Thrombophilia Work-Up and Clinical Outcomes in Indian Patients With Unprovoked Venous and Arterial Thrombosis Aged 18-50 Years. Bleeding, Thrombosis, and Vascular Biology, 2026, 5, 1-8.	0.3	0
84	Evaluating the Impact of Obesity and Epicardial Adiposity on the Presence of HFpEF in Patients With AF. JACC: Clinical Electrophysiology, 2026, 12, 96-107.	4.2	4
85	Outcomes in Patients With Atrial Fibrillation Stratified by Body Mass Index and Heart Failure Status. JACC: Advances, 2026, 5, 102531.	3.2	0
86	Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. Journal of the American College of Cardiology, 2026, 88, 1255-1283.	12.0	4
87	Anticoagulation Dilemma in a Patient With Pulmonary Embolism and Massive Haemoptysis. Cureus, 2026, .	1.3	0